Protocol for Using Bamlanivimab + Etesevimab Anti-SARC-CoVID-2 Monoclonal Antibodies
National Plan, Policy & Guidelines

Protocol for Using Bamlanivimab + Etesevimab Anti-SARC-CoVID-2 Monoclonal Antibodies

admin November 7, 2021 1 min read
Save

The Bamlanivimab+Etesevimab are anti-SARC-COVID-2 monoclonal antibodies which have received Emergency Use Authorization (EUA) from US FDA as well as conditional […]

The Bamlanivimab+Etesevimab are anti-SARC-COVID-2 monoclonal antibodies which have received Emergency Use Authorization (EUA) from US FDA as well as conditional use approval from the MoHP, Department of Drug Administration (DDA) in Nepal.

DOWNLOAD PDF FILE

COVID-19 COVID19 Monoclonal Antibodies National Plan Policy Guidelines Policy & Guidelines Protocol
Save
Share this
X WhatsApp Telegram LinkedIn
Back to all news

Related Articles

PEN-Plus Orientation Manual for Mid-Level Health Care Workers
National Plan, Policy & Guidelines

PEN-Plus Orientation Manual for Mid-Level Health Care Workers

Overview The Epidemiology and Disease Control Division (EDCD) has officially released a new standardized orientation manual under the Package of…

Aug 15, 2026
National Health Training Strategy 2082
National Plan, Policy & Guidelines

National Health Training Strategy 2082

The National Health Training Centre (NHTC) has outlined the strategic direction for Nepal’s health workforce capacity development under the newly…

Aug 15, 2026
Simulation Accreditation Manual for Clinical Training Sites
National Plan, Policy & Guidelines

Simulation Accreditation Manual for Clinical Training Sites

Overview The National Health Training Centre (NHTC) has officially released the Simulation Accreditation Manual for Clinical Training Sites, introducing a…

Aug 15, 2026